Cagrilintide 10mg

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity (NCT06780449)

Research Applications & Benefits

• the phase iiia redefine 1 trial found that once-weekly cagrisema produced unprecedented weight reductions in adults with overweight or obesity, with 60% achieving ≥20% weight loss and 23% losing 30% or more. it also significantly improved systolic blood pressure, waist circumference, lipid levels, and glycemic control.
• Clinical Implication: highlights the exceptional efficacy of cagrisema in achieving substantial weight loss and broad cardiometabolic benefits, setting a new benchmark for anti-obesity medications.

Primary Research Areas

• Obesity
• Type 2 Diabetes
• Amylin Receptor Agonism
• Weight Loss & Glucose Control
• Fat Mass Reduction & Lean Mass Preservation
• Food Intake Modulation
• Neuronal Activation (DVC, LPBN)